Center News

HIV Vaccine Trials Network relaunches publication

Newsletter highlights clinical trial research, protocols in the field and the network's mission to drive the development of a safe, globally effective vaccine to prevent HIV

Sept. 12, 2011

This month, the HIV Vaccine Trials Network is reintroducing the HVTNews. The publication will highlight the progress of this international collaboration of scientists and educators who are searching for an effective and safe HIV vaccine.

"In this and future editions, we will clarify why HIV vaccine research in humans provides critical momentum for the discovery and development of effective vaccines," said Dr. Jim Kublin, executive director.

Access a pdf of the new HVTN publication here. The publication will also be available under "What’s new on Center websites" section of the Center News Weekly home page.

In addition to highlights from recent HVTN publications, and announcements of upcoming meetings and conferences, this edition of the newsletter features the following articles:

  • A Sequential Two-stage Trial Design for Evaluating Efficacy and Immune Correlates for Multiple Vaccine Regimens
  • Sieve Analysis of HIV Sequences in Vaccine Efficacy Trials
  • Training and Mentorship Programs at the HVTN
  • Defining the Targets of HIV-specific T-Cell Responses (Epitope Mapping)
  • The 2011 HVTN Annual Network Award Winners
  • HVTN 505: Expansion in Response to an Evolving Field
  • Exploring Barriers and Facilitators to Participation of Male-To-Female Transgender Persons in HIV Vaccine Clinical Trials

Headquartered at the Hutchinson Center, the Network’s HIV Vaccine Trial Units are located at leading research institutions in 27 cities on four continents and led by internationally renowned HIV vaccine and prevention investigators.

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.